Aan dit artikel is enkele uren gewerkt. Opzoeken, vertalen, plaatsen enz. Als u ons wilt ondersteunen dan kan dat via een al of niet anonieme donatie. Elk bedrag is welkom hoe klein ook. Klik hier als u ons wilt helpen kanker-actueel online te houden. Wij zijn een ANBI organisatie dus uw donatie is aftrekbaar voor de belasting.

15 december 2012: op zoek naar het volledige studierapport van onderstaande studie kwam ik op de website van dr. Lamm, de oncoloog die onderstaande studie uitvoerde en al jaren gelden een prive kliniek begon:
 
1. Megadose vitamins in bladder cancer: a double-blind clinical trial.
Lamm DL; Riggs DR; Shriver JS; vanGilder PF; Rach JF; DeHaven JI
Department of Urology, West Virginia University School of Medicine, Morgantown.
J Urol 1994 Jan;151(1):21-6 PMID: 8254816 UI: 94076504

Op zijn website  beveelt dr. Lamm een tablet 'oncovite' aan die als volgt is samengesteld uit bepaalde vitamine sen  mineralen en wordt vergeleken met de dagelijks aanbevolen hoeveelheid: Onder de tabel van 'oncovite' een grafiek over het verloop van de eerder genoemde studie bij wel en niet gebruik van multivitamines. Helemaal onderaan een referentielijst van de belangrijkste studies die dr. Lamm deed bij blaaskanker:

Ingredients of Oncovite, current formulation:*

Component RDA
Reference Value*		 Oncovite
Amount/tablet
Vitamin A 5,000 IU 9,000 IU
Vitamin C 60 mg 500 mg
Vitamin D3 400 IU 400 IU
Vitamin E 30 IU 100 IU
Thiamine 1.5 mg 0.34 mg
Riboflavin 1.7 mg 0.5 mg
Niacin 20 mg 5 mg
Vitamin B6 2.0 mg 25 mg
Folate 0.4 mg 0.4 mg
Vitamin B12 6 mcg 1.6 mcg
Pantothenic Acid 10 mg 2.3 mg
Zinc 15 mg 7.5 mg

Graph 

 

Blaaskanker en vitamines:
Lamm is een bekende reguliere onderzoeker, en vond in de USA, na verwijdering van de eerste oppervlakkige blaastumor, binnen vijf jaar zoals verwacht  toch minstens 1 nieuwe tumor (= recidief) bij 91% van de personen, ondanks toepassing van een standaard reguliere immunotherapie. Maar alleen door simpele toevoeging van enkele megadoses vitamines (A,B6,C,E) en een mineraal (zink) zou nog maar 41% binnen 5 jaar een nieuwe tumor hebben gehad, dus 59% in het geheel geen nieuw recidief binnen die tijd. Het onderzoek met de toevoeging werd zelfs eerder dan 5 jaar afgebroken, het zou beslist niet ethisch zijn geweest de zieke controlegroep zonder vitamines en zink dit nog langer te ontzeggen.

Hier het abstract van deze studie:

J Urol. 1994 Jan;151(1):21-6.

Megadose vitamins in bladder cancer: a double-blind clinical trial.

Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI.

Source

Department of Urology, West Virginia University School of Medicine, Morgantown.

Abstract

Epidemiological and laboratory studies suggest that vitamin supplements may be helpful in the prevention of some cancers but clinical trials to date have failed to demonstrate protection with naturally occurring vitamins. Without substantiation of the highly touted benefits of vitamins, few physicians who care for cancer patients have recommended their use. A total of 65 patients with biopsy confirmed transitional cell carcinoma of the bladder enrolled in a randomized comparison of intravesical bacillus Calmette-Guerin (BCG) with or without percutaneous administration was also randomized by closed envelope to therapy with multiple vitamins in the recommended daily allowance (RDA) versus RDA multivitamins plus 40,000 units vitamin A, 100 mg. vitamin B6, 2,000 mg. vitamin C, 400 units vitamin E and 90 mg. zinc. The addition of percutaneous BCG did not significantly lessen tumor recurrence but recurrence after 10 months was markedly reduced in patients receiving megadose vitamins. The 5-year estimates of tumor recurrence are 91% in the RDA arm and 41% in the megadose arm (p = 0.0014, Mantel-Cox). Overall recurrence was 24 of 30 patients (80%) in the RDA arm and 14 of 35 (40%) in the high dose arm (p = 0.0011, 2-tailed Fisher's exact test). Megadose vitamins A, B6, C and E plus zinc decrease bladder tumor recurrence in patients receiving BCG immunotherapy. Further research will be required to identify which ingredient(s) provide this protection.

PMID:
8254816
[PubMed - indexed for MEDLINE]

References of studies for bladder cancer

Publications

Dr. Lamm's bibliography includes more than 270 publications. Below is a partial list that represents Dr. Lamm's areas of interest and expertise.

Selected Publications

  1. Lamm DL, Harris SC and Gittes RF: Bacillus Calmette-Guerin and Dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. Invest Urology 14:369, 1977.
  2. Lamm DL, Reichert DF, Radwin HM and Thor DE: Bacillus Calmette-Guerin immunotherapy of the cancer-contaminated wound. J Surg Res 27(1):14-22, 1979.
  3. Lamm DL, Yee GN, Reichert DF and Radwin HM: Levamisole immunotherapy of experimental transitional cell carcinoma. Invest Urol 16(4):286-288, 1979.
  4. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD and Radwin HM: BCG immunotherapy of superficial bladder cancer. J Urol 124(1):38-40, 1980.
  5. Lamm DL, Reyna JA and Reichert DF: Keyhole-Limpet Hemocyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol Res 9(5):227-230, 1981.
  6. Lamm DL, Thor DE, Winters WD, Stogdill VD and Radwin HM: BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses. Cancer 48(1):82-88, 1981.
  7. Lamm DL, Thor DE, Stogdill VD and Radwin HM: Bladder cancer immunotherapy. J Urol 128(5):931-935, 1982.
  8. Lamm DL, Reichert FD, Harris SC and Lucio RM: Immunotherapy of murine transitional cell carcinoma. J Urol 128(5):1104-1108, 1982.
  9. Lamm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134(1):40-47, 1985.
  10. Lamm DL: Bacillus Calmette-Guerin immunotherapy. J Urol 138(2): 391-392, 1987.
  11. Lamm DL: BCG in carcinoma in situ and superficial bladder tumors. EORTC Genitourinary Group Monograph 5: Progress and Controversies in Oncological Urology II. Prog Clin Biol Res 269:497-507, 1988.
  12. Lamm DL, Crissman J, Blumenstein B, et al: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study. Prog Clin Biol Res 310(11):263-270, 1989.
  13. Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D and Sarosdy MF: A randomized prospective comparison of oral versus intravesical and percutaneous Bacillus Calmette-Guerin for superficial bladder cancer. J Urol 144(1):65-67, 1990.
  14. Lamm DL, Riggs DR, DeHaven JI and Bryner RW: Immunotherapy of murine bladder cancer by irradiated tumor vaccine. J Urol 145(1):195-198, 1991.
  15. Lamm DL, DeHaven JI, Shriver J and Sarosdy MF: Prospective randomized comparison of intravesical with percutaneous Bacillus Calmette-Guerin versus intravesical Bacillus Calmette-Guerin in superficial bladder cancer. J Urol 145(4):738-740, 1991.
  16. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan, J, Sarosdy, MF, Crissman, JD and Coltman, CA: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. New Engl J Med 325(17):1205-1209, 1991
  17. Lamm DL, DeHaven JI, Riggs DR and Ebert RF: Immunotherapy of murine bladder cancer with Keyhole Limpet Hemocyanin (KLH). J Urol 149(3):648-652, 1993.
  18. Lamm DL, DeHaven JI, Riggs DR, Delgra A, and Burrell R: Immunotherapy of Murine Transitional Cell Carcinoma with Immucothel, a Modification of Keyhole Limpet Hemocyanin (KLH). Urol Res 21: 21-33, 1993.
  19. Lamm DL, Riggs DR, Shriver JS, VanGilder PF, Rach JF and DeHaven JI: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151(1):21-26, 1994.
  20. Lamm DL, Riggs DR, Traynelis CT and Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444-50, 1995.
  21. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, and Grossman, HB: Randomized Intergroup Comparison of Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Chemotherapy PrRophylaxis in Superficial Transitional Cell Carcinoma of the Bladder. A Southwest Oncology Group Study. Urol Oncol 1:119-126, 1995.
  22. Riggs DR, DeHaven JI and Lamm DL: Allium sativum (garlic) Treatment for Murine Transitional Cell Carcinoma. Cancer 79(10):1987-1994, 1997.
  23. Lamm DL: Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin 48(5): 263-268, 1998
  24. Lamm DL, Riggs DR, Donley MS, White J, Yeater R, and Bryner RW: Bacillus Calmette-Guerin Immunotherapy Significantly Prolongs Survival of Animals with Prostate Cancer. The Prostate Journal 1(4): 190-194, 1999.
  25. Lamm DL and Riggs DR: The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 27(1): 157-162, 2000.
  26. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, and Crawford ED: Maintenance bacillus Calmette-Guerin immunoterapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4): 1124-1129, 2000.
  27. Lamm DL: Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 31 Suppl 3:S86-90, 2000.
  28. Hogan TF, Lamm DL, Ducatman AM. Smoking and renal cell carcinoma. W V Med J. 97(1):32-5, 2001.
  29. Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA: Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev. 25(1):62-75, 2001.
  30. Kamat AM, Lamm DL: Immunotherapy for bladder cancer. Curr Urol Rep. 2(1):62-9, 2001.
  31. Kamat AM, Lamm DL: Chemoprevention of bladder cancer. Urol Clin North Am. 29(1):157-68, 2002.
  32. Lamm DL: Superficial bladder cancer. Curr Treat Options Oncol. 3(5):403-11, 2002.
  33. Sylvester RJ, van der MEIJDEN AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 168(5):1964-70, 2002.
  34. Simon SD, Ferrigni RG, Novicki DE, Lamm DL, Swanson SS, Andrews PE: Mayo Clinic Scottsdale experience with laparoscopic nephron sparing surgery for renal tumors. J Urol. 169(6):2059-62, 2003.
  35. Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology. 63(3):457-60, 2004.
  36. Simon SD, Castle EP, Ferrigni RG, Lamm DL, Swanson SK, Novicki DE, Andrews PE: Complications of laparoscopic nephrectomy: the Mayo clinic experience. J Urol. 171:1447-50, 2004.
  37. Schenkman E, Lamm DL. Superficial bladder cancer therapy. ScientificWorldJournal. 1 (Suppl):387-99, 2004.

dr. Lamm, blaaskanker


Plaats een reactie ...

Reageer op "Vitamines en mineralen: Extra grote doses vitamines en zink naast BCG - bacillus Calmette-Guerin voorkomt hoog significant een recidief bij blaaskankerpatienten. 59 procent minder recidieven na 5 jaar.."


Gerelateerde artikelen
 

Gerelateerde artikelen

Blaaskanker en vitamines: >> Blaaskanker en vitamines: >> Vitamine E vermindert kans >> Vitamine E lijkt risico op >> Complementair - niet-toxisch >>